Joseph K. Belanoff
Net Worth
Last updated:
What is Joseph K. Belanoff net worth?
The estimated net worth of Dr. Joseph K. Belanoff is at least $220,736,261 as of 31 Jul 2024. He owns shares worth $176,300,597 as insider, has earned $12,515,664 from insider trading and has received compensation worth at least $31,920,000 in Corcept Therapeutics Incorporated.
What is the salary of Joseph K. Belanoff?
Dr. Joseph K. Belanoff salary is $1,520,000 per year as Co-Founder, Pres, Chief Executive Officer & Director in Corcept Therapeutics Incorporated.
How old is Joseph K. Belanoff?
Dr. Joseph K. Belanoff is 68 years old, born in 1957.
What stocks does Joseph K. Belanoff currently own?
As insider, Dr. Joseph K. Belanoff owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Corcept Therapeutics Incorporated (CORT) | Co-Founder, Pres, Chief Executive Officer & Director | 2,483,107 | $71 | $176,300,597 |
What does Corcept Therapeutics Incorporated do?
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Joseph K. Belanoff insider trading
Corcept Therapeutics Incorporated
Dr. Joseph K. Belanoff has made 103 insider trades between 2004-2024, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 800,000 units of CORT stock on 22 Jan 2021. As of 31 Jul 2024 he still owns at least 2,483,107 units of CORT stock.